Company intelligence / Profile preview

GMP Endotherapeutics

Ownership: Private
Development stage: Other

Overview

GMP Endotherapeutics has funded research into pancreatic beta cell growth factors with the goal of developing products for diabetes. At least one candidate, the INGAP peptide, has reached early-stage human clinical testing focused on safety and tolerability in diabetic patients. No recent data is available regarding later-stage results.

Therapeutic areas: Endocrinology
Modalities: Peptide
Industry: Biotech

Partnerships

Academic collaboration with Eastern Virginia Medical School

Beyond the preview

Go deeper on GMP Endotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GMP Endotherapeutics.

Explore the full profile